Epirubicin hydrochloride and Breast cancer metastatic - a phase IV clinical study of FDA data

Summary:

Breast cancer metastatic is found among people who take Epirubicin hydrochloride, especially for people who are 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Epirubicin hydrochloride and have Breast cancer metastatic. It is created by eHealthMe based on reports of 3,214 people who have side effects when taking Epirubicin hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 30, 2022

3,214 people reported to have side effects when taking Epirubicin hydrochloride.
Among them, 18 people (0.56%) have Breast cancer metastatic.

What is Epirubicin hydrochloride?

Epirubicin hydrochloride has active ingredients of epirubicin hydrochloride. eHealthMe is studying from 3,232 Epirubicin hydrochloride users for its effectiveness, alternative drugs and more.

What is Breast cancer metastatic?

Breast cancer metastatic is found to be associated with 840 drugs and 449 conditions by eHealthMe.

Number of Epirubicin hydrochloride and Breast cancer metastatic reports submitted per year:

Could Epirubicin hydrochloride cause Breast cancer metastatic?

Time on Epirubicin hydrochloride when people have Breast cancer metastatic *:

Age of people who have Breast cancer metastatic when taking Epirubicin hydrochloride *:

Common drugs people take besides Epirubicin hydrochloride *:

Common side effects people have besides Breast cancer metastatic *:

Malignant Neoplasm Progression (cancer tumour came back): 9 people, 50.00%
Disease Progression: 7 people, 38.89%
Metastases To Liver (cancer spreads to liver): 5 people, 27.78%
Metastases To Bone (cancer spreads to bone): 4 people, 22.22%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 16.67%
Cough: 2 people, 11.11%
Lymphangiosis Carcinomatosa (inflammation of the lymph vessels can lead to cancer): 2 people, 11.11%
Metastases To Lung (cancer spreads to lung): 2 people, 11.11%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 11.11%
Metastases To The Mediastinum (cancer spreads to mediastinum): 2 people, 11.11%

Common conditions people have *:

Breast Cancer: 6 people, 33.33%
Metastases To Bone (cancer spreads to bone): 3 people, 16.67%
Metastases To Lung (cancer spreads to lung): 1 person, 5.56%
Metastases To Liver (cancer spreads to liver): 1 person, 5.56%
Breast Cancer Stage Ii: 1 person, 5.56%
Breast Cancer Female: 1 person, 5.56%
Adverse Event: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Epirubicin hydrochloride and have Breast cancer metastatic?

Check whether Breast cancer metastatic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of Epirubicin hydrochloride:

Epirubicin hydrochloride (3,232 reports)

Breast cancer metastatic treatments and more:

Breast cancer metastatic (63,641 reports)

COVID vaccines that are related to Breast cancer metastatic:

How severe was Breast cancer metastatic and when was it recovered:

Breast cancer metastatic in Epirubicin hydrochloride

Expand to all the drugs that have ingredients of epirubicin hydrochloride:

Breast cancer metastatic and drugs with ingredients of epirubicin hydrochloride

Common drugs associated with Breast cancer metastatic:

Abraxane: 286 reports
Afinitor: 369 reports
Ambien: 137 reports
Anastrozole: 249 reports
Aredia: 310 reports
Arimidex: 213 reports
Aromasin: 325 reports
Aspirin: 191 reports
Ativan: 125 reports
Avastin: 203 reports
Avonex: 147 reports
Calcium: 127 reports
Capecitabine: 514 reports
Carboplatin: 258 reports
Coumadin: 162 reports
Cyclophosphamide: 259 reports
Cycrin: 430 reports
Cytoxan: 124 reports
Decadron: 225 reports
Dexamethasone: 185 reports
Dilaudid: 117 reports
Docetaxel: 245 reports
Effexor: 112 reports
Estrace: 273 reports
Everolimus: 188 reports
Exemestane: 531 reports
Faslodex: 480 reports
Femara: 358 reports
Fluorouracil: 185 reports
Fosamax: 208 reports
Gabapentin: 109 reports
Gemzar: 110 reports
Herceptin: 389 reports
Humira: 120 reports
Hydrochlorothiazide: 134 reports
Ibrance: 461 reports
Ibuprofen: 127 reports
Lasix: 151 reports
Letrozole: 997 reports
Lipitor: 115 reports
Lisinopril: 122 reports
Loraz: 105 reports
Lorazepam: 105 reports
Lyrica: 114 reports
Medroxyprogesterone acetate: 878 reports
Metformin: 137 reports
Methotrexate: 218 reports
Morphine: 203 reports
Navelbine: 191 reports
Neurontin: 112 reports
Nexium: 121 reports
Ogen: 108 reports
Omeprazole: 136 reports
Oxycodone: 110 reports
Oxycontin: 143 reports
Paclitaxel: 305 reports
Pantoprazole: 118 reports
Prednisone: 146 reports
Premarin: 3,252 reports
Premphase: 141 reports
Premphase 14/14: 107 reports
Prempro: 3,297 reports
Prilosec: 121 reports
Profen: 127 reports
Protonix: 149 reports
Provera: 2,473 reports
Synthroid: 206 reports
Tamoxifen citrate: 225 reports
Taxol: 254 reports
Taxotere: 255 reports
Tykerb: 235 reports
Vicodin: 144 reports
Vitamin d: 105 reports
Xanax: 115 reports
Xeloda: 574 reports
Xgeva: 288 reports
Zofran: 165 reports
Zoladex: 130 reports
Zoledronic acid: 126 reports
Zoloft: 104 reports
Zometa: 780 reports

How the study uses the data?

The study uses data from the FDA. It is based on epirubicin hydrochloride (the active ingredients of Epirubicin hydrochloride) and Epirubicin hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.